Products for Research Use Only

SB 242084

CAT: 0804-HY-13409-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13409-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SB 242084 is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier) . SB 242084 increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage[1][2][3].
CAS Number
181632-25-7
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
5-HT Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Metabolic Disease; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/SB-242084.html
Purity
99.96
Solubility
DMSO : ≥ 44 mg/mL
Smiles
O=C(N1CCC2=C1C=C(Cl)C(C)=C2)NC3=CC=C(OC4=CC=CN=C4C)N=C3
Molecular Formula
C21H19ClN4O2
Molecular Weight
394.85
Precautions
H315, H319, H335
References & Citations
[1]Kennett GA, et al. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology. 1997 Apr-May;36 (4-5) :609-20. |[2]Harmon JL, et al. 5-HT2 Receptor Regulation of Mitochondrial Genes: Unexpected Pharmacological Effects of Agonists and Antagonists. J Pharmacol Exp Ther. 2016 Apr;357 (1) :1-9. |[3]Kennett GA, et al. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology. 1997 Apr-May;36 (4-5) :609-20.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
5-HT2 Receptor; α-1 microglobulin
Citation 01
Authorea. September 19, 2022.|Biochem Biophys Res Commun. 2024 May 23:722:150074.|Biochem Pharmacol. 2025 Oct 13:117421.|Neuroendocrinology. 2024 May 8.|Brain. 2024 Nov 4;147 (11) :3764-3779.|Eur J Pharmacol. 2025 Nov 5:1006:178170.